Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 30.34% and Operating profit at -271.37% over the last 5 years
3
With a growth in Operating Profit of 141.72%, the company declared Outstanding results in Mar 25
4
With ROE of -2.90%, it has a risky valuation with a 8.88 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,931 Million (Large Cap)
NA (Loss Making)
NA
0.00%
0.55
0.43%
7.21
Revenue and Profits:
Net Sales:
268 Million
(Quarterly Results - Sep 2025)
Net Profit:
41 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.74%
0%
1.74%
6 Months
-16.03%
0%
-16.03%
1 Year
76.45%
0%
76.45%
2 Years
138.43%
0%
138.43%
3 Years
1.21%
0%
1.21%
4 Years
5.58%
0%
5.58%
5 Years
-7.43%
0%
-7.43%
Shenzhen Chipscreen Biosciences Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
30.34%
EBIT Growth (5y)
-271.37%
EBIT to Interest (avg)
-4.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.22
Tax Ratio
23.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
1.36%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.88
EV to EBIT
-159.08
EV to EBITDA
-807.85
EV to Capital Employed
6.58
EV to Sales
18.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.14%
ROE (Latest)
-2.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
267.60
179.00
49.50%
Operating Profit (PBDIT) excl Other Income
51.50
19.90
158.79%
Interest
9.40
9.00
4.44%
Exceptional Items
0.20
-0.70
128.57%
Consolidate Net Profit
41.20
-10.10
507.92%
Operating Profit Margin (Excl OI)
192.40%
16.90%
17.55%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 49.50% vs 67.29% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 507.92% vs 78.78% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
655.80
515.80
27.14%
Operating Profit (PBDIT) excl Other Income
0.90
-138.20
100.65%
Interest
34.40
35.00
-1.71%
Exceptional Items
-90.00
0.80
-11,350.00%
Consolidate Net Profit
-114.60
49.20
-332.93%
Operating Profit Margin (Excl OI)
-92.40%
-356.50%
26.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 27.14% vs -2.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -332.93% vs 284.37% in Dec 2023
About Shenzhen Chipscreen Biosciences Co., Ltd. 
Shenzhen Chipscreen Biosciences Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






